Skip to main content
OpenTrials
Completed

NCT Number: NCT03605082

A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

The purpose of the study is to evaluate the safety and tolerability and serum Pharmacokinetics (PK) of single doses of UCB0107 administered in healthy Japanese subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Japanese Volunteers

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Up0065 001

London, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is male or female, >=20 and <=75 years of age
  • Subject is of Japanese descent as evidenced by appearance and verbal confirmation of familial heritage (a subject has all 4 Japanese grandparents born in Japan)
  • Subject has a body mass index (BMI) >=18.0 and <=30.0 kg/m^2, with a body weight of at least 50 kilogram (kg) for males and 45 kg for females, and maximum 100 kg
  • Subject is in good physical and mental health, in particular is not affected by any neurological disorder, in the opinion of the Investigator, as determined on the basis of medical history and a general clinical examination at Screening
  • Subject has clinical laboratory test results within the reference ranges of the laboratory
  • Subject has Blood pressure and pulse rate within normal range in supine position after 5 minutes rest
  • Subject's electrocardiogram (ECG) is considered "normal," or "abnormal" but clinically nonsignificant (as interpreted by the Investigator)

Exclusion criteria

  • Subject has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or electrocardiogram, which, in the opinion of the Investigator, may place the subject at risk because of participation in the study
  • Subject has a history of recurrent headaches, including migraine
  • Subject has a history of alcohol and/or drug abuse up to 6 months before Screening
  • Subject smokes on average >5 cigarettes/day (or equivalent) during the last 3 months and is not able to stop smoking during the In-Clinic Period
  • Subject has any clinically relevant brain magnetic resonance imaging (MRI) abnormality at Screening
  • Subject has >upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35%)
  • Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 2 years
  • Subject has a positive serology test for hepatitis B surface antigen, hepatitis B core antibodies, hepatitis C virus antibodies or antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 at Screening
  • Subject has a known hypersensitivity to any components of the investigational medicinal product (IMP), comparative drugs, any biologic or small molecule, or concomitant medication as stated in this protocol
  • Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study or within 6 months following the final dose of the IMP

Treatment and study plan

UCB0107

Drug
  • Pharmaceutical form: solution for infusion
  • Route of administration: intravenous use

Placebo

Other
  • Pharmaceutical form: solution for infusion
  • Route of administration: intravenous use

Primary outcomes

  1. The incidence of treatment-emergent adverse events during the study from first dose of UCB0107 to safety follow-up/withdraw

    Time frame: From first dose of UCB0107 to safety follow-up/withdraw on day 140 +/-4 days

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

  2. Maximum observed serum concentration of UCB0107 during the study

    Time frame: The blood sampling time points for serum Pharmacokinetics will be as follows: predose (<=60 minutes before dosing); end of infusion, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose; and on Day 7, 14, 28, 42, 56, 84 and 140

    Pharmacokinetic variable:

    Cmax: maximum observed serum concentration

  3. Area under the concentration-time curve from time 0 to infinity of UCB0107 during the study

    Time frame: The blood samples for serum Pharmacokinetics will be taken from predose to Day 140

    Pharmacokinetic variable:

    AUC: area under the concentration-time curve from time 0 to infinity

  4. Area under the concentration-time curve from time 0 to time t of UCB0107 during the study

    Time frame: The blood sampling time points for serum Pharmacokinetics will be as follows: predose (<=60 minutes before dosing); end of infusion, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose; and on Day 7, 14, 28, 42, 56, 84 and 140

    Pharmacokinetic variable:

    AUC(0-t): area under the concentration-time curve from time 0 to time t, the time of the last quantifiable concentration

  5. Terminal half-life of UCB0107 during the study

    Time frame: The blood sampling time points for serum Pharmacokinetics will be as follows: predose (<=60 minutes before dosing); end of infusion, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose; and on Day 7, 14, 28, 42, 56, 84 and 140

    Pharmacokinetic variable:

    t1/2: terminal half-life

  6. Volume of distribution of UCB0107 during the study

    Time frame: The blood sampling time points for serum Pharmacokinetics will be as follows: predose (<=60 minutes before dosing); end of infusion, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose; and on Day 7, 14, 28, 42, 56, 84 and 140

    Pharmacokinetic variable:

    Vz: volume of distribution

  7. The clearance of UCB0107 during the study

    Time frame: The blood sampling time points for serum Pharmacokinetics will be as follows: predose (<=60 minutes before dosing); end of infusion, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose; and on Day 7, 14, 28, 42, 56, 84 and 140

    Pharmacokinetic variable:

    CL: clearance

  8. The time to maximum observed serum concentration of UCB0107 during the study

    Time frame: The blood sampling time points for serum Pharmacokinetics will be as follows: predose (<=60 minutes before dosing); end of infusion, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours postdose; and on Day 7, 14, 28, 42, 56, 84 and 140

    Pharmacokinetic variable:

    tmax: time to maximum observed serum concentration

Sponsors and collaborators

Lead sponsor

UCB Biopharma S.P.R.L.

Industry

Registry information

Official study title

A Single-center, Investigator-blind, Subject Blind, Randomized, Placebo-controlled Study to Evaluate Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jul 30, 2018
Registry last updated
Mar 14, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.